SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 102 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $6,031,000 | -19.1% | 6,264,420 | 0.0% | 0.71% | -2.3% |
| Q1 2022 | $7,455,000 | -63.5% | 6,264,420 | 0.0% | 0.72% | -55.3% |
| Q4 2021 | $20,422,000 | -21.0% | 6,264,420 | +8.3% | 1.62% | +1.0% |
| Q3 2021 | $25,859,000 | -18.0% | 5,785,036 | 0.0% | 1.60% | -22.4% |
| Q2 2021 | $31,528,000 | -27.1% | 5,785,036 | 0.0% | 2.07% | -15.7% |
| Q1 2021 | $43,272,000 | -31.1% | 5,785,036 | 0.0% | 2.45% | -37.8% |
| Q4 2020 | $62,768,000 | – | 5,785,036 | – | 3.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,439,895 | $18,747,000 | 4.66% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $31,528,000 | 2.07% |
| Omega Fund Management, LLC | 2,274,831 | $12,398,000 | 1.40% |
| Altium Capital Management LP | 1,076,942 | $5,869,000 | 1.36% |
| Samsara BioCapital, LLC | 2,189,199 | $10,599,000 | 1.31% |
| Sio Capital Management, LLC | 800,000 | $4,360,000 | 1.08% |
| Flagship Pioneering Inc. | 2,938,494 | $16,015,000 | 0.20% |
| EcoR1 Capital, LLC | 1,000,000 | $5,450,000 | 0.20% |
| Artal Group S.A. | 1,700,000 | $9,265,000 | 0.19% |
| ACT CAPITAL MANAGEMENT, LLC | 52,500 | $287,000 | 0.15% |